Scholarlink

<p>Apical membrane sodium transporters in renal proximal tubules, such as sodium-glucose co-transporter 2, are attractive therapeutic targets for the treatment of heart failure (HF). Sodium-phosphate co-transporter 2a (NaPi2a) is predominantly expressed in the apical membrane of proximal tubular epithelia and functions to reabsorb filtered phosphate and sodium. It currently remains unclear whether the inhibition of NaPi2a attenuates HF. We found that NaPi2a deficiency improved the cardiac phenotypes of the HF models of transverse aortic constriction (TAC) and doxorubicin (Dox) cardiotoxicity. Natriuretic and phosphaturetic effects were observed in NaPi2a-KO mice under normal conditions, resulting in low serum phosphate and fibroblast growth factor-23 (FGF23) levels. In the TAC and Dox models, the left ventricular ejection fraction was preserved in NaPi2a-KO mice, while FGF23 levels did not correlate with cardiac hypertrophy. A qPCR analysis of heart tissue showed increases in the mRNA expression of fetal myocardial and tissue fibrosis markers in the TAC and Dox models, and decreases in NaPi2a-KO mice. The present results demonstrated that NaPi2a-mediated natriuresis, rather than decreases in serum FGF23 levels through its phosphaturic effects, may be responsible for attenuating myocardial injury and cardiac tissue fibrosis in the TAC and Dox-induced HF models in NaPi2a-KO mice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic deletion of the sodium phosphate cotransporter NaPi2a ameliorates heart failure in mice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月14日

查看全文
  • Hiroko Yamauchi-Sawada,
  • Tomoharu Ida,
  • Masashi Nakamura,
  • Minato Umehara,
  • Natsuko Okuno-Ozeki,
  • Itaru Nakamura,
  • Yayoi Matoba,
  • Atsushi Minamida,
  • Yasuto Sunahara,
  • Tomohiro Nakata,
  • Kunihiro Nakai,
  • Aya Yagi-Tomita,
  • Noriko Uehara-Watanabe,
  • Noriyuki Yamashita,
  • Yuhei Kirita,
  • Keiichi Tamagaki,
  • Benjamin D. Humphreys,
  • Satoaki Matoba,
  • Tetsuro Kusaba

摘要

Apical membrane sodium transporters in renal proximal tubules, such as sodium-glucose co-transporter 2, are attractive therapeutic targets for the treatment of heart failure (HF). Sodium-phosphate co-transporter 2a (NaPi2a) is predominantly expressed in the apical membrane of proximal tubular epithelia and functions to reabsorb filtered phosphate and sodium. It currently remains unclear whether the inhibition of NaPi2a attenuates HF. We found that NaPi2a deficiency improved the cardiac phenotypes of the HF models of transverse aortic constriction (TAC) and doxorubicin (Dox) cardiotoxicity. Natriuretic and phosphaturetic effects were observed in NaPi2a-KO mice under normal conditions, resulting in low serum phosphate and fibroblast growth factor-23 (FGF23) levels. In the TAC and Dox models, the left ventricular ejection fraction was preserved in NaPi2a-KO mice, while FGF23 levels did not correlate with cardiac hypertrophy. A qPCR analysis of heart tissue showed increases in the mRNA expression of fetal myocardial and tissue fibrosis markers in the TAC and Dox models, and decreases in NaPi2a-KO mice. The present results demonstrated that NaPi2a-mediated natriuresis, rather than decreases in serum FGF23 levels through its phosphaturic effects, may be responsible for attenuating myocardial injury and cardiac tissue fibrosis in the TAC and Dox-induced HF models in NaPi2a-KO mice.